VIVUS
CompanyUnited StatesFounded 1991
VIVUS develops 6 assets, the furthest approved (PANCREAZE in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions). Mostly small molecule and protein or enzyme acting on PDE5A; based in the United States, founded in 1991.
- 6
- Assets
- Furthest stage
- Approved
- 32
- Trials
- 10
- Signals
Pipeline
6Provides pancreatic enzyme therapy.
Approved, Protein or enzyme, exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Combines phentermine-mediated appetite suppression with topiramate to reduce food intake and promote weight loss.
Approved, Small molecule, obesity, excess body weight
Approved, Small molecule, excess body weight, obesity
3 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms6
- Trials33
- Signals20
- Similar companies6
Papers
Obesity (Silver Spring, Md.), Jan 21, 2026